| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Leslie Citrome, Josephine Cucchiaro, Kaushik Sarma, Debra Phillips, Robert Silva, Satoru Tsuchiya, Antony Loebe. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. International clinical psychopharmacology. vol 27. issue 3. 2012-07-24. PMID:22395527. |
long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. |
2012-07-24 |
2023-08-12 |
Not clear |
| Leslie Citrome, Josephine Cucchiaro, Kaushik Sarma, Debra Phillips, Robert Silva, Satoru Tsuchiya, Antony Loebe. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. International clinical psychopharmacology. vol 27. issue 3. 2012-07-24. PMID:22395527. |
the aim of this study is to evaluate the long-term safety and tolerability of lurasidone in the treatment of schizophrenia. |
2012-07-24 |
2023-08-12 |
Not clear |
| Leslie Citrome, Josephine Cucchiaro, Kaushik Sarma, Debra Phillips, Robert Silva, Satoru Tsuchiya, Antony Loebe. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. International clinical psychopharmacology. vol 27. issue 3. 2012-07-24. PMID:22395527. |
clinically stable adult outpatients with schizophrenia were randomized in a 2 : 1 ratio to 12 months of double-blind treatment with once-daily, flexibly-dosed lurasidone (40-120 mg) or risperidone (2-6 mg). |
2012-07-24 |
2023-08-12 |
Not clear |
| Joshua T Kantrowitz, Leslie Citrom. Lurasidone for schizophrenia: what's different? Expert review of neurotherapeutics. vol 12. issue 3. 2012-06-11. PMID:22364325. |
lurasidone for schizophrenia: what's different? |
2012-06-11 |
2023-08-12 |
Not clear |
| Joshua T Kantrowitz, Leslie Citrom. Lurasidone for schizophrenia: what's different? Expert review of neurotherapeutics. vol 12. issue 3. 2012-06-11. PMID:22364325. |
lurasidone is one of several antipsychotics approved in the recent past by the us fda for the treatment of schizophrenia. |
2012-06-11 |
2023-08-12 |
Not clear |
| Eunice Y Yuen, Xiangning Li, Jing Wei, Masakuni Horiguchi, Herbert Y Meltzer, Zhen Ya. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses. Molecular pharmacology. vol 81. issue 2. 2012-05-04. PMID:22072817. |
in this study, we found that lurasidone, as well as the prototypical atypical apd clozapine, restored nmdar-mediated synaptic responses to normal levels in the pcp model of schizophrenia. |
2012-05-04 |
2023-08-12 |
rat |
| Eunice Y Yuen, Xiangning Li, Jing Wei, Masakuni Horiguchi, Herbert Y Meltzer, Zhen Ya. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses. Molecular pharmacology. vol 81. issue 2. 2012-05-04. PMID:22072817. |
these results suggest that nmdar is the potential key molecular target of lurasidone, possibility via antagonizing 5-ht(7) receptors, which is consistent with evidence that 5-ht(7) receptor antagonism contributes to cognitive enhancement by atypical apds in patients with schizophrenia. |
2012-05-04 |
2023-08-12 |
rat |
| R T Owe. Lurasidone: a new treatment option for schizophrenia. Drugs of today (Barcelona, Spain : 1998). vol 47. issue 11. 2012-03-06. PMID:22146224. |
lurasidone: a new treatment option for schizophrenia. |
2012-03-06 |
2023-08-12 |
Not clear |
| R T Owe. Lurasidone: a new treatment option for schizophrenia. Drugs of today (Barcelona, Spain : 1998). vol 47. issue 11. 2012-03-06. PMID:22146224. |
lurasidone is a novel benzoisothiazol antipsychotic that has recently been approved for the treatment of schizophrenia in the u.s. like many other second-generation antipsychotics, it has a high affinity for dopamine d(2) and serotonin 5-ht(2a) receptors as well as a high affinity for 5-ht(7) receptors. |
2012-03-06 |
2023-08-12 |
Not clear |
| R T Owe. Lurasidone: a new treatment option for schizophrenia. Drugs of today (Barcelona, Spain : 1998). vol 47. issue 11. 2012-03-06. PMID:22146224. |
a short-term, head-to-head trial of lurasidone versus ziprasidone in chronic stable schizophrenia was also conducted. |
2012-03-06 |
2023-08-12 |
Not clear |
| John M Kan. Lurasidone: a clinical overview. The Journal of clinical psychiatry. vol 72 Suppl 1. 2012-02-23. PMID:22217440. |
lurasidone is a new second-generation (atypical) antipsychotic approved for the treatment of schizophrenia in adults. |
2012-02-23 |
2023-08-12 |
Not clear |
| John M Kan. Lurasidone: a clinical overview. The Journal of clinical psychiatry. vol 72 Suppl 1. 2012-02-23. PMID:22217440. |
lurasidone may be particularly helpful for patients with schizophrenia who are overweight or have endocrine problems (diabetes, dyslipidemia) or comorbid cardiovascular conditions. |
2012-02-23 |
2023-08-12 |
Not clear |
| Steven G Potkin, Masaaki Ogasa, Josephine Cucchiaro, Antony Loebe. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophrenia research. vol 132. issue 2-3. 2012-02-09. PMID:21889878. |
double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. |
2012-02-09 |
2023-08-12 |
Not clear |
| Steven G Potkin, Masaaki Ogasa, Josephine Cucchiaro, Antony Loebe. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophrenia research. vol 132. issue 2-3. 2012-02-09. PMID:21889878. |
the current study evaluated the safety and efficacy of lurasidone and ziprasidone in stable outpatients diagnosed with schizophrenia or schizoaffective disorder. |
2012-02-09 |
2023-08-12 |
Not clear |
| L Citrom. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. International journal of clinical practice. vol 65. issue 2. 2011-12-22. PMID:21129135. |
lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. |
2011-12-22 |
2023-08-12 |
Not clear |
| L Citrom. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. International journal of clinical practice. vol 65. issue 2. 2011-12-22. PMID:21129135. |
to describe the efficacy and safety of lurasidone for the treatment of schizophrenia. |
2011-12-22 |
2023-08-12 |
Not clear |
| Martin P Cru. Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia. P & T : a peer-reviewed journal for formulary management. vol 36. issue 8. 2011-11-10. PMID:21935296. |
lurasidone hcl (latuda), an oral, once-daily atypical antipsychotic agent for the treatment of patients with schizophrenia. |
2011-11-10 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, Josephine Cucchiaro, Robert Silva, Masaaki Ogasa, Debra Phillips, Jane Xu, Amir H Kalali, Edward Schweizer, Andrei Pikalov, Antony Loebe. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. The American journal of psychiatry. vol 168. issue 9. 2011-10-31. PMID:21676992. |
lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. |
2011-10-31 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, Josephine Cucchiaro, Robert Silva, Masaaki Ogasa, Debra Phillips, Jane Xu, Amir H Kalali, Edward Schweizer, Andrei Pikalov, Antony Loebe. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. The American journal of psychiatry. vol 168. issue 9. 2011-10-31. PMID:21676992. |
the study was designed to evaluate the short-term efficacy and safety of lurasidone in the treatment of acute schizophrenia. |
2011-10-31 |
2023-08-12 |
Not clear |
| Ludovic Samalin, Marion Garnier, Pierre-Michel Llorc. Clinical potential of lurasidone in the management of schizophrenia. Therapeutics and clinical risk management. vol 7. 2011-07-14. PMID:21753886. |
clinical potential of lurasidone in the management of schizophrenia. |
2011-07-14 |
2023-08-12 |
Not clear |